Citigroup Inc Sarepta Therapeutics, Inc. Transaction History
Citigroup Inc
- $196 Billion
- Q2 2025
A detailed history of Citigroup Inc transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 210,320 shares of SRPT stock, worth $3.84 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
210,320
Previous 383,827
45.2%
Holding current value
$3.84 Million
Previous $24.5 Million
85.32%
% of portfolio
0.0%
Previous 0.01%
Shares
16 transactions
Others Institutions Holding SRPT
# of Institutions
479Shares Held
89.5MCall Options Held
1.41MPut Options Held
1.19M-
Black Rock Inc. New York, NY10.3MShares$189 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.16MShares$167 Million0.0% of portfolio
-
State Street Corp Boston, MA4.07MShares$74.3 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X03.36MShares$61.5 Million0.12% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.67MShares$48.9 Million2.76% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.6B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...